AC IMMUNE SA SF-02 (IMR) — Capital Reinvestment Ratio

Latest as of December 2024: 0.02x

AC IMMUNE SA SF-02 (IMR) has a Capital Reinvestment Ratio of 0.02x as of December 2024, meaning it reinvests 0% of its operating cash flow (€5.93 Million) in capital expenditures (€90.00K). See IMR equity financing ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.02x
Capex / Operating Cash Flow

Operating Cash Flow

€5.93 Million
EUR

Capital Expenditures

€90.00K
EUR

Data as of

Dec 2024
Most recent filing

AC IMMUNE SA SF-02 Capital Reinvestment Ratio (2024–2024)

This chart tracks AC IMMUNE SA SF-02's Capital Reinvestment Ratio across 1 annual periods. Check IMR total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for AC IMMUNE SA SF-02 (2024–2024)

Year-by-year Capital Reinvestment Ratio for AC IMMUNE SA SF-02 from 2024 to 2024. For live market cap and broader valuation context, see market value of AC IMMUNE SA SF-02.

Year Reinvestment Ratio Operating CF (EUR) Capital Expenditures YoY Change
2024 0.01x €65.84 Million €576.00K
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow